Home > Healthcare > Analytical Instruments > Molecular Analysis > solid tumor testing market
Get a free sample of Solid Tumor Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Solid Tumor Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Based on type, the market is segmented into genetic testing and conventional testing. The genetic testing segment dominated the market in 2023 and accounted for USD 13.6 billion.
Based on application, the solid tumor testing market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, melanoma, and other applications. The breast cancer segment dominated the market in 2023 with a market share of 25.9%.
Based on end-use, the solid tumor testing market is segmented into hospitals, diagnostics laboratories, cancer research institutes, and other end-users. The hospitals segment is anticipated to reach USD 13.8 billion by 2032.
North America solid tumor testing market accounted for USD 7.7 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.3% between 2024 to 2032.
The U.S. held a dominant position in the solid tumor testing market, with a revenue of USD 7.1 billion in 2023.
UK solid tumor testing market is anticipated to witness substantial growth during 2024 to 2032 timeframe.
Japan holds a dominant position in the Asia Pacific solid tumor testing market.
The genetic testing segment dominated the market in 2023, accounting for USD 13.6 billion.
The solid tumor testing industry was valued at approximately USD 20.5 billion in 2023 and is estimated to grow at a 7.6% CAGR from 2024 to 2032, driven by rising cancer incidences and increased awareness.
The North America market generated USD 7.7 billion in revenue from solid tumor testing in 2023 and is anticipated to grow at a CAGR of 7.3% from 2024 to 2032. This growth is fueled by the region's advanced healthcare system and access to state-of-the-art diagnostic technologies.
Key players in the industry include Abbott, Agilent Technologies, Inc., Caris Life Sciences, F. Hoffmann-La Roche Ltd, Foundation Medicine, Inc., Guardant Health, Hologic, Inc., Illumina, Inc., MedGenome, and Myriad Genetics, Inc.